Clinical and Laboratory Assessment of the Complex Treatment of Blepharitis Using Photodynamic Therapy
Abstract
Blepharitis is a common inflammatory eyelid disease, particularly in its chronic form, which is resistant to therapy.
The aim. To optimize the comprehensive treatment of blepharitis using photodynamic therapy (PDT).
Material and methods. The study involved 60 patients divided into control and main groups. The control group received standard therapy, including a 0.02% furacilin solution, warm compresses, and 1% tetracycline ointment. The main group, in addition to standard treatment, underwent photodynamic therapy.
Results and discussins. The combined use of photodynamic therapy accelerated inflammation resolution – by day 3 the index decreased by 2.72 times, and by day 7 inflammation was absent in all patients. Eyelid swelling and hyperemia resolved by days 3-4 (compared to 7 days in the control group). Pathogenic microflora was absent in 82.4% of patients by days 4-5 (compared to 7–8 days in the control group).
Conclusions. Photodynamic therapy effectively eliminates inflammation, improves the clinical picture in 82.4% of patients, and reduces treatment duration by 5-6 days.
About the Authors
K. I. Narzikulova
Ташкентская медицинская академия
Russian Federation
Russian Federation
F. A. Bakhritdinova
Ташкентская медицинская академия
Russian Federation
Russian Federation
R. K. Baratova
Ташкентская медицинская академия
Russian Federation
Russian Federation
S. Kh. Nazirova
Ташкентская медицинская академия
Russian Federation
Russian Federation
References
1. Avetisova SE, Egorova EA, Moshetova LK, Neroeva VV, Takhchidi HP. Oftal'mologiya. Natsional'noe rukovodstvo [Ophthalmology. National Guide]. Moscow: GEOTAR-Media; 2019. 752 p. (in Russ).
2. Pasechnikova NV, Zborovskaya AV, Pilkevich TS. Photodynamic therapy with methylene blue as a new direction in the treatment of infectious and inflammatory eye diseases. Science and Practice: Interdepartmental Medical Journal. 2014;2/3:72-7. (in Russ).
3. Rapacka-Zdończyk A, Woźniak A, Michalska K, Pierański M, Ogonowska P, Grinholc M, Nakonieczna J. Factors determining the susceptibility of bacteria to antibacterial photodynamic inactivation. Front Med. 2021;8:617. (in Engl)
4. Somov EE. Klinicheskaya anatomiya organa zreniya cheloveka [Clinical anatomy of the human visual organ]. Moscow; 2016. 134 p. (in Russ).
5. Filatova NV. Fotodinamicheskaya terapiya v lechenii neovaskulyarizatsii rogovitsy u detei [Photodynamic therapy in the treatment of corneal neovascularization in children] [dissertation]. Moscow; 2012. 26 p. (in Russ).
6. Chekhova TA, Chernykh VV. Ophthalmic rosacea: etiology, pathogenesis, new approaches to therapy. Ophthalmic Surgery. 2016;2:54-8. (in Russ). doi: 10.25276/0235-4160-2016-2-54-59
7. Shurubey VA, Teplyuk NP, Smirennaya EV. Clinical manifestations and treatment of blepharitis and dry eye syndrome in rosacea. Cataract and Refractive Surgery. 2014;14(2):38-44. (in Russ).
8. Almeida A. Photodynamic therapy in the inactivation of microorganisms. Antibiotics. 2020;9:138. (in Engl)
9. Chimenti MS, Triggianese P, Salandri G, Conigliaro P, Canofari C, Caso F, et al. A multimodal eye assessment in psoriatic arthritis patients sine psoriasis: Evidence for a potential association with systemic inflammation. J Clin Med. 2020 Mar;9(3):719. (in Engl) doi: 10.3390/jcm9030719
10. Chisholm SAM, Couch SM, Custer PL. Etiology and Management of Allergic Eyelid Dermatitis. Ophthalmic Plast Reconstr Surg. 2017;33(4):248-50. (in Engl) doi: 10.1097/IOP.0000000000000723
11. Constantin M, Ciurduc M, Bucur S, Olteanu R, Ionescu RA, Constantin T, Furtunescu F. Psoriasis beyond the skin: Ophthalmological changes (Review). Exp Ther Med. 2021 Sep;22(3):981. (in Engl) doi: 10.3892/etm.2021.10413
12. Ha M, Song J, Park S, Han K, Hwang HS, Kim HS, et al. Relationship between serum lipid level and meibomian gland dysfunction subtype in Korea using propensity score matching. Sci Rep. 2021 Aug;9(11(1)):16102. (in Engl) doi: 10.1038/s41598-021-95599-y.
13. Lange N, Szlasa W, Saczko J, Chwiłkowska A. Potential of cyanine derived dyes in photodynamic therapy. Pharmaceutics. 2021;13:818. (in Engl)
14. Lapp T, Maier P, Jakob T, Reinhard T. Pathophysiology of atopic blepharokeratoconjunctivitis. Ophthalmologe. 2017 Jun;114(6):504- 13. (in Engl) doi: 10.1007/s00347-017-0483-1
15. Lu LJ. Human Microbiota and Ophthalmic Disease. Yale J Biol Med. 2016 Sep;89(3):325-30. (in Engl)
16. Montaseri H, Kruger CA, Abrahamse H. Inorganic nanoparticles applied for active targeted photodynamic therapy of breast cancer. Pharmaceutics. 2021;13:296. (in Engl)
17. Tariq R, Khalid UA, Kanwal S, Adnan F, Qasim M. Photodynamic therapy: A rational approach toward COVID-19 management. J Explor Res Pharmacol. 2021;6:44–52. (in Engl)
18. Yoo SW, Oh G, Ahn JC, Chung E. Non-oncologic applications of nanomedicine-based phototherapy. Biomedicines. 2021;9:113. (in Engl)
19. Zhao X, Liu J, Fan J, Chao H, Peng X. Recent progress in photosensitizers for overcoming the challenges of photodynamic therapy: From molecular design to application. Chem Soc Rev. 2021;50:4185–219. (in Engl)
Review
For citations:
Narzikulova K.I., Bakhritdinova F.A., Baratova R.K., Nazirova S.Kh. Clinical and Laboratory Assessment of the Complex Treatment of Blepharitis Using Photodynamic Therapy. Bashkortostan Medical Journal. 2025;20(2):5-8. (In Russ.)
Views:
10
Email this article 
